New River Pharmaceuticals Inc

New River Pharmaceuticals — Technical Presentation (June 2006)

8 slides from New River Pharmaceuticals's technical presentation, Jun 20, 2006

  1. Slide 1: Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104)

    Slide 1: Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104)

    Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA NRP lisdexamfetamine dimesylate (LDX) NRP104 • Pharmacologically inactive pro-drug in which d-

  2. Slide 2: Systolic Blood Pressure

    Slide 2: Systolic Blood Pressure

    Do you like the drug effect you are feeling now? Systolic Blood Pressure

  3. Slide 3: Mean Score

    Slide 3: Mean Score

    Mean Score Mean Score’ Placebo d-amphetamine 10mg _ NRPI04 26 mg

  4. Slide 4: Treatment Enjoyment Assessment and Cohort 1 Findings

    Slide 4: Treatment Enjoyment Assessment and Cohort 1 Findings

    Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA NEW RIVER PROTOCOL NRP104.A02 TREATMENT ENJOYMENT ASSESSMENT QUESTIONNAIRE DRUG CHOSEN TO TAKE

  5. Slide 5: Mean d-amphetamine Concentration-Time

    Slide 5: Mean d-amphetamine Concentration-Time

    PK data Cohort 2 Mean d-amphetamine Concentration -Time Plots

  6. Slide 6: Systolic Blood Pressure

    Slide 6: Systolic Blood Pressure

    Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA Do you like the drug effect you are feeling now? Systolic Blood Pressure

  7. Slide 7: d-amphetamine 20 mg vs Placebo

    Slide 7: d-amphetamine 20 mg vs Placebo

    d-amphetamine 20, Placebo "WAP 104 50 m 5 pore 91095 ueeW ¥ 91095 useW

  8. Slide 8: Analysis of Maximum Effect

    Slide 8: Analysis of Maximum Effect

    Abuse Liability of Intravenous L-lysine-d-amphetamine (NRP104) Jasinski, D.R.1; Krishnan, S.2 1 Medicine, Johns Hopkins University, Baltimore, MD, USA.;2 New River Pharmaceuticals Inc., Blacksburg, VA, USA Analysis of Maximum Effect Based upon ANOVA Dependent Variable Do you like the drug effect you

Source: SEC EDGAR · 8-K filed Jun 20, 2006

More decks from New River Pharmaceuticals Inc